Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. reports company developments as a medical device company focused on epilepsy care through the RNS System, a brain-responsive neuromodulation platform that monitors brain electrical activity and delivers personalized electrical stimulation at the seizure source. Recurring updates cover RNS System revenue, financial results, gross margin, research and development spending, and corporate outlook commentary.
NeuroPace news also includes clinical evidence for drug-resistant focal epilepsy and broader epilepsy programs, including post-approval study publications and NAUTILUS trial presentations. Additional announcements include healthcare conference presentations, investor communications, product-platform development, AI-enabled tools, and other clinical or regulatory disclosures tied to responsive neurostimulation.
NeuroPace (Nasdaq: NPCE) announced that its management team will participate in the 2026 Cantor Global Healthcare Conference. The team will join a fireside chat on Wednesday, September 9 at 10:55 a.m. EDT and host one-on-one investor meetings. The fireside chat will be available via live webcast, with a replay posted in the Events section of NeuroPace’s investor website.
NeuroPace (Nasdaq: NPCE) announced that its management team will participate in the Wells Fargo 21st Annual Healthcare Conference. The team will join a fireside chat on Tuesday, September 8 at 8:00am EDT and hold one-on-one investor meetings. The discussion will be available via live webcast and later replay on the Events section of NeuroPace’s investor website.
NeuroPace (Nasdaq: NPCE) reported second quarter 2026 revenue of $22.8 million, up 17% year over year, including $22.5 million in RNS System revenue, a 21.3% increase. GAAP net loss from continuing operations narrowed to ($6.2) million from ($10.0) million, and non-GAAP net loss improved to ($3.9) million from ($6.8) million.
Non-GAAP gross margin was 83.4% and non-GAAP operating expenses were $21.9 million. The company ended June 30, 2026 with $51.9 million in cash, cash equivalents, short-term investments and restricted cash, and $59.0 million in long-term borrowings.
NeuroPace raised 2026 revenue guidance to $99.5–$101.5 million, increased non-GAAP gross margin guidance to 82.0–83.0%, and improved Adjusted EBITDA guidance to ($7.5)–($8.5) million. Operationally, it launched its AI-based ECoG Assistant, published 18‑month NAUTILUS data, and reported record prescribers and patient pipeline.
NeuroPace (Nasdaq: NPCE) reported that the FDA has determined its Premarket Approval (PMA) Panel Track Supplement to expand the labeled indication of the RNS System to drug‑resistant idiopathic generalized epilepsy (IGE) is not approvable in its current form and requested additional clinical evidence, including further NAUTILUS trial data and literature context.
According to NeuroPace, the FDA has invited continued dialogue, recommended a Submission Issue Request (SIR), and the company plans to amend the submission with supplemental information. The PMA is supported by NAUTILUS 18‑ and 24‑month data showing substantial reductions in generalized tonic‑clonic and other seizure types and high patient and physician‑reported improvement rates.
NeuroPace (Nasdaq: NPCE) will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting in Cleveland, Ohio, from May 29 – June 2, 2026.
The company will showcase responsive neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, thalamic neuromodulation, and its FDA-approved AI tool ECoG Assistant.
NeuroPace (Nasdaq: NPCE) received FDA approval for ECoG Assistant, its first AI-driven, clinician-enabled feature for RNS therapy. Built on long-term intracranial EEG data, it helps identify ECoGs of Interest and supports faster treatment decisions. A next-generation, cloud-based PDMS is also under FDA review, with expected approval in Q2 2026.
NeuroPace (Nasdaq: NPCE) reported Q1 2026 revenue of $22.1 million, including $0.1 million from DIXI Medical. Non-GAAP revenue excluding DIXI grew 20.1% year over year to $22.0 million, with RNS System revenue of $21.7 million, up 19.5%.
GAAP net loss was ($6.7) million; non-GAAP net loss was ($4.4) million. The company raised 2026 revenue guidance to $99–$101 million, assumes 21–23% RNS growth, and modestly improved Adjusted EBITDA guidance to a loss of ($8.5)–($9.5) million.
NeuroPace (Nasdaq: NPCE) will report first quarter 2026 financial results after market close on May 12, 2026.
A live webcast and conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET; telephone participation is available with Conference ID 8467256. The webcast will be archived on the investor site and replayable for at least 90 days.
NeuroPace (NASDAQ: NPCE) reported publication of 3-year Post-Approval Study results showing an 82% median seizure reduction in drug-resistant focal epilepsy and presented 12- and 18-month NAUTILUS data at AAN 2026 showing a 77% median reduction in generalized tonic-clonic seizures at 18 months.
NAUTILUS also showed declines in injury events (~30%), a 44% lower benzodiazepine rescue use (p<0.001), and >80% Clinical Global Impression of Change at 18 months.
NeuroPace (Nasdaq: NPCE) said its management will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 1:30pm ET (10:30am PT).
The presentation will be available via live webcast and a replay will remain available for thirty days in the Events & Presentations section of NeuroPace's investor website.